Premium
Eradicating tumor drug resistance at its YAP ‐biomechanical roots
Author(s) -
Zanconato Francesca,
Piccolo Stefano
Publication year - 2015
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.15252/embj.201593584
Subject(s) - mechanotransduction , biology , melanoma , cancer research , drug resistance , mechanism (biology) , microbiology and biotechnology , cytoskeleton , acquired resistance , mutant , vemurafenib , kinase , cell , genetics , metastatic melanoma , gene , philosophy , epistemology
Treatment with BRAF kinase inhibitors leads to rapid resistance and tumor regression in BRAF V600E mutant melanoma patients. However, the underlying mechanism of the developed tumor resistance is not fully clear. In this issue of The EMBO Journal , Kim and colleagues show that melanoma cells acquire resistance to BRAF inhibitors by changing cell shape, modifying their cytoskeleton and, in turn, activating the YAP / TAZ mechanotransduction pathway (Kim et al , [Kim MH, 2016]).